What characterizes hospital-acquired or ventilator-associated pneumonia and how does this affect empiric antibiotic choice?

• A. Onset after 48 hours of hospitalization or in ventilated patients; risk for MDR pathogens; empiric therapy should cover MRSA and Pseudomonas with broader-spectrum agents.
• B. Occurs only in ICU; only MRSA coverage needed.
• C. Within 24 hours of admission; narrow-spectrum.
• D. Defined by community onset; no MRSA coverage.

Answer: (A)

The key idea is that pneumonia acquired in the hospital setting, including when a patient is on a ventilator, is often caused by multidrug-resistant organisms such as Pseudomonas and MRSA. Because these pathogens are more common in this environment, the initial (empiric) antibiotics must be broad enough to cover both Pseudomonas and MRSA until culture results are available.

Hospital-acquired pneumonia is defined by onset 48 hours or more after admission (not present at the time of admission), and ventilator-associated pneumonia occurs in patients who are being mechanically ventilated. These contexts expose patients to resistant flora and the hospital environment, making narrow therapy inappropriate at first.

Therefore, the usual empiric approach is to start with a broad anti-pseudomonal regimen plus coverage for MRSA, choosing agents appropriate for the local resistance patterns (often an anti-pseudomonal beta-lactam such as piperacillin-tazobactam, cefepime, ceftazidime, or a carbapenem, with MRSA coverage via vancomycin or linezolid). Therapy can be de-escalated later based on culture results and patient response. The exact choice is guided by local antibiograms and patient risk factors for MDR pathogens.

Other options don’t fit because they misstate the timing (within 24 hours or community onset), the setting (not limited to ICU), or the antibiotic coverage (MRSA alone or no MRSA coverage), all of which overlook the MDR risk inherent to hospital- and ventilator-associated pneumonias.